Acute monocytic leukemia News and Research

RSS

Study compares cord blood to bone marrow for transplants

Umbilical cord blood transplants may offer blood cancer patients better outcomes than bone marrow transplants, according to an analysis of outcome data performed at the Statistical Center, Center for Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee.

14 Jun 2007

Patients with myelodysplastic syndromes treated with Revlimid are living longer and remaining transfusion independent

New updated results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) were presented by Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, at the 9th International Symposium on MDS currently taking place in Florence, Italy.

18 May 2007

Translocation kidney cancer after chemotherapy in childhood

This article out of Johns Hopkins reviewed the risk of renal cell carcinoma occurring as a secondary malignancy after chemotherapy in childhood.

21 Apr 2007

New discoveries about stem cells in leukemia, breast and colon cancer

Recent discoveries about the role of stem cells in cancer have altered the landscape of cancer research. With each new study, scientists are learning more about cancer-initiating properties of stem cells at organ sites and throughout the body.

19 Apr 2007

Polymorphisms in the glutathione S-transferase genes and treatment outcomes in acute myeloid leukemia

Levels of an enzyme involved metabolizing chemotherapy may help patients with acute myeloid leukemia (AML) to be able to better tolerate chemotherapy, according to the results of research which will be presented by Kirsten Moysich, PhD, Department of Epidemiology, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

18 Apr 2007

Experimental drug provides powerful therapy against acute myeloid leukemia

Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.

19 Nov 2006

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.

11 Apr 2006

ChemGenex Pharmaceuticals receives U.S. orphan drug designation for Ceflatonin

ChemGenex Pharmaceuticals has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug status for the company's most advanced drug, Ceflatonin, for the treatment of chronic myeloid leukemia (CML).

21 Mar 2006

Study recommends treatment change for pre-leukemia disease

A new study finds that longer courses of a mild form of chemotherapy may help patients with a bone marrow disease only recently considered a form of cancer.

14 Mar 2006

Decitabine improves myelodysplastic syndrome treatment

A potent member of a new class of drugs increases survival in some patients with myelodysplastic syndrome (MDS), and may become the new standard of therapy for this group of pre-cancer disorders

14 Mar 2006

Decitabine improves patient outcomes in myelodysplastic syndromes

Decitabine, a new drug undergoing Phase III efficacy trials, provides palliative therapy for patients with the bone marrow disease called Myelodysplastic Syndrome (MDS), according to a new study.

14 Mar 2006

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

Scientists at the Johns Hopkins Kimmel Cancer Center have found that a gene pathway linked to a deadly form of leukemia may provide a new way to treat autoimmune diseases, including multiple sclerosis.

2 Dec 2005

Acute-leukemia sign may signal need for different therapy

A type of chromosome change that was thought to predict a good response to treatment in patients with acute myeloid leukemia (AML) might actually signal the need for a different therapy to achieve the best outcome.

19 Sep 2005

Discovery of new gene FANCM sheds light on repair of damaged DNA

National Institute on Aging (NIA) researchers have discovered a new gene, FANCM, which sheds light on an important pathway involved in the repair of damaged DNA.

22 Aug 2005

Data directly support a pathogenetic model of acute leukemia

Acute myeloid leukemia (AML) is frequently caused by genetic alterations that affect transcription factors, such as AML1-ETO and mutations affecting genes involved in signal transduction pathways, such as FLT3.

15 Jul 2005

Long-term outcomes studied for stem cell transplant recipients

Improved techniques and supportive care have resulted in a growing number of long-term survivors of stem cell transplants, though little is known about the impact transplants have on patients’ lives long after treatment.

23 May 2005

Giving children access to drug clinical trials is crucial, clofarabine approval shows

The accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) demonstrates the importance of offering children rapid access to new treatments through clinical trials, according to investigators at St. Jude Children's Research Hospital. Refractory or relapsed ALL is a disease that resists treatment.

2 May 2005

Enzyme that helps trigger the development of leukemia

Scientists at the University of North Carolina at Chapel Hill have identified an enzyme that helps trigger the development of leukemia, a cancer of blood cells.

21 Apr 2005

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Researchers have discovered that specific cancer-causing genes associated with leukemias can transform mature white blood cells into leukemic cells that have all the properties of stem cells.

21 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004